about
Post-Genomics and Vaccine Improvement for LeishmaniaA Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against ExpeVector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular ApproachesComparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.Combination of In Silico Methods in the Search for Potential CD4(+) and CD8(+) T Cell Epitopes in the Proteome of Leishmania braziliensis.
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Using humans to make a human leishmaniasis vaccine.
@en
Using humans to make a human leishmaniasis vaccine.
@nl
type
label
Using humans to make a human leishmaniasis vaccine.
@en
Using humans to make a human leishmaniasis vaccine.
@nl
prefLabel
Using humans to make a human leishmaniasis vaccine.
@en
Using humans to make a human leishmaniasis vaccine.
@nl
P2860
P1476
Using humans to make a human leishmaniasis vaccine
@en
P2093
Jesus G Valenzuela
Shaden Kamhawi
P2860
P304
P356
10.1126/SCITRANSLMED.3009118
P407
P577
2014-04-01T00:00:00Z